 |
|
|
| |
METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks
|
| |
| |
Reported by Jules Levin
18th Intl AIDS Conference
July 18-23 2010 Vienna Austria
Judith Aberg, MD1, Turner Overton, MD2, Samir Gupta, MD3, Ron Falcon, MD4, Robert Ryan, MS5, Guy De La Rosa, MD4
1Bellevue Hospital Center at New York University, New York, NY, USA; 2Washington University School of Medicine, St. Louis, MO, USA; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Tibotec
Therapeutics, Titusville, NJ, USA; 5Tibotec Inc, Titusville, NJ, USA
AUTHOR SUMMARY
AUTHOR CONCLUSION
Figure 2. Lipid parameters at baseline and Week 12
In Figure 2A, dashed lines represent the National Cholesterol Education Program criteria12:
Trig ≥150mg/dL, TC ≥200mg/dL, LDL ≥130mg/dL, HDL ≤40mg/dL for men and ≤50mg/dL for women; an=28; bn=27; cn=27; dTo convert from mg/dL to mmol/L, divide mg/dL value by the following conversion factors: Trig=88.6; TC, LDL or HDL=38.7. To convert apoA1 and apoB from mg/dL to g/L, divide by 100; DRV/r, darunavir/low-dose ritonavir; BL, baseline;
Wk, week; ATV/r, atazanavir/low-dose ritonavir; Trig, triglycerides; TC, total cholesterol;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CI, confidence interval;
Apo, apolipoprotein
aITT-observed (sample size varies by time point and parameter); ITT, intent-to-treat; DRV/r, darunavir/low-dose ritonavir; ATV/r, atazanavir/low-dose ritonavir; BL, baseline; Wk, week; CI, confidence interval; HOMA-IR, homeostasis model assessment of insulin resistance; SD, standard deviation; IL, interleukin; hs-CRP, high sensitivity C-reactive protein; TNF-α, tumor necrosis factor-alpha; LPS, lipopolysaccharide
|
| |
|
|
|
|
|
